Baxter International has completed production of its first commercial batches of Celvapan A/H1N1 pandemic vaccine and is discussing distribution plans with national health authorities, subject to obtaining authorizations. Celvapan is made using the company’s Vero cell culture technology. The company was able to produce the vaccine within 12 weeks of receiving the A/H1N1 virus strain. Baxter plans to deliver initial quantities of the vaccine to national health authorities that have placed orde...